Personalis Gross Margin 2018-2024 | PSNL

Current and historical gross margin for Personalis (PSNL) over the last 10 years. The current gross profit margin for Personalis as of June 30, 2024 is %.
Personalis Gross Margin Historical Data
Date TTM Revenue TTM Gross Profit Gross Margin
2024-06-30 $0.08B $0.02B 25.93%
2024-03-31 $0.08B $0.02B 24.00%
2023-12-31 $0.07B $0.02B 24.32%
2023-09-30 $0.07B $0.02B 21.13%
2023-06-30 $0.07B $0.01B 20.59%
2023-03-31 $0.07B $0.01B 18.84%
2022-12-31 $0.07B $0.01B 18.46%
2022-09-30 $0.07B $0.02B 26.09%
2022-06-30 $0.08B $0.02B 31.58%
2022-03-31 $0.08B $0.03B 35.00%
2021-12-31 $0.09B $0.03B 36.05%
2021-09-30 $0.09B $0.03B 34.12%
2021-06-30 $0.08B $0.03B 31.33%
2021-03-31 $0.08B $0.02B 28.75%
2020-12-31 $0.08B $0.02B 25.64%
2020-09-30 $0.08B $0.02B 27.63%
2020-06-30 $0.07B $0.02B 30.14%
2020-03-31 $0.07B $0.02B 32.86%
2019-12-31 $0.07B $0.02B 35.38%
2019-06-30 $0.04B $0.01B 33.33%
2019-03-31 $0.04B $0.01B 28.57%
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.270B $0.073B
Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $20.902B 7.10
Dr Reddy's Laboratories (RDY) India $12.399B 18.57
BridgeBio Pharma (BBIO) United States $4.791B 0.00
Bausch Health Cos (BHC) Canada $3.597B 2.61
Amphastar Pharmaceuticals (AMPH) United States $2.469B 13.82
Supernus Pharmaceuticals (SUPN) United States $1.872B 377.44
Taysha Gene Therapies (TSHA) United States $0.314B 51.00
Assembly Biosciences (ASMB) United States $0.107B 0.00
Acasti Pharma (GRCE) Canada $0.031B 0.00
Sol-Gel Technologies (SLGL) Israel $0.014B 0.00
Evoke Pharma (EVOK) United States $0.005B 0.00
Teligent (TLGT) United States $0.000B 0.00